Aug. 2 at 1:28 AM
Heads up alert! Upcoming earnings on Tuesday, 8/5/2025 for
$AMGN
Neutral (5.3)
---
Amgen Inc.
(NASDAQ: AMGN) is currently experiencing a period of moderate investor sentiment, reflected in its neutral consensus signal.
The company has recently announced a dividend of
$2.38 per share for the third quarter of 2025, reinforcing its commitment to shareholder returns.
Amgen's strategic focus includes diversifying its therapeutic portfolio, evidenced by its acquisition of Horizon Therapeutics, which aims to mitigate the impact of upcoming patent expirations from older drugs like Enbrel.
However, the company faces challenges such as pricing pressures from biosimilar competition and political scrutiny on drug pricing.
Despite these challenges, its pipeline remains robust, with promising developments like the positive Phase 3 results for Bemarituzumab in gastric cancer.
Financially, Amgen's P/E ratio and EPS growth are competitive, though it trades at a premium compared to its peers, which is a point of contention among analysts.
The company's revenue forecasts show modest growth, aligning with broader industry trends but signaling cautionary optimism given the competitive landscape.
---
Amgen is set to report its second-quarter 2025 earnings on August 5, with Wall Street anticipating continued earnings growth driven by strong drug volumes.
Historically, Amgen has a strong track record of earnings surprises, and analysts are optimistic about another potential beat this quarter.
The focus will likely be on how the company manages pricing pressures and biosimilar headwinds, which could impact margins.
The consensus estimates point to single-digit growth in profit, reflecting cautious optimism amid market uncertainties.
Any deviation from these expectations could significantly influence the stock's short-term performance.
---
The biotechnology sector, to which Amgen belongs, has been experiencing a challenging period with stalled rallies and price volatility.
The SPDR S&P Biotech ETF has shown frustrating price action for investors, reflecting broader concerns about the sector's growth prospects.
Despite these challenges, companies with strong pipelines and strategic alliances, like Amgen, have the potential to outperform.
However, the sector's overall performance remains subdued, with political and regulatory factors continuing to influence investor sentiment.
- Funds were net sellers of
$AMGN during the previous reporting quarter.
- Funds with large holdings in
$AMGN include:
- Aristotle Capital Management LLC, MV:
$1,154MM. Fund Rank: 77%
www.aristotlecap.com
- Canada Pension , MV:
$161MM. Fund Rank: 76%
- Adage Capital P, MV:
$70MM. Fund Rank: 86%
www.adagecapital.com
- ARK Investment Management LLC, MV:
$18MM. Fund Rank: 85%
www.ark-invest.com
- DEAN CAPITAL MANAGEMENT, MV:
$4MM. Fund Rank: 65%
www.deancapmgmt.com
- Last 10 days performance: -3%
- Last 30 days performance: -1%
- Last 90 days performance: 6%
Some of the latest news articles:
- Title: McDonald’s, Palantir, Novo Nordisk Earnings: What to Watch Next Week
Publication Date: 8/1/2025 8:38:36 PM, Source: yahoo
URL: https://finance.yahoo.com/m/2320cff2-8e3a-3a57-abdf-ddec6cad507c/mcdonald%E2%80%99s%2C-palantir%2C-novo.html?.tsrc=rss
- Title: AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
Publication Date: 8/1/2025 8:01:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/amgen-announces-2025-third-quarter-200100530.html?.tsrc=rss
- Title: Stocks to watch next week: BP, Diageo, Disney, Uber and WPP
Publication Date: 8/1/2025 3:38:41 PM, Source: yahoo
URL: https://uk.finance.yahoo.com/news/bp-diageo-disney-uber-wpp-stocks-watch-153517077.html?.tsrc=rss
- Title: Stocks Erase Early Gains as Chip Makers and Big Pharma Retreat
Publication Date: 7/31/2025 8:32:27 PM, Source: yahoo
URL: https://www.barchart.com/story/news/33792613/stocks-erase-early-gains-as-chip-makers-and-big-pharma-retreat?.tsrc=rss
Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal.
